{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:24:37Z","timestamp":1780511077755,"version":"3.54.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1914,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","award":["16\/11\/00420"],"award-info":[{"award-number":["16\/11\/00420"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","award":["16\/11\/00403"],"award-info":[{"award-number":["16\/11\/00403"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","award":["16\/11\/00420"],"award-info":[{"award-number":["16\/11\/00420"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","award":["16\/11\/00403"],"award-info":[{"award-number":["16\/11\/00403"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the safety profile in terms of changes in renal function after co-treatment with sacubitril\/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril\/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal function (WRF)\/improved renal function (IRF) was included in the primary endpoint. WRF and IRF were defined as an increase\/decrease in serum creatinine \u2265 0.3 mg\/dL or GFR \u2265 20%. Changes in quantitative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 \u00b1 6% and 70 \u00b1 28 mL\/min\/1.73 m2, respectively. At a median follow-up of 1.01 years (inter-quartile range 0.71\u20131.50), 377 outpatient visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The co-administration of sacubitril\/valsartan and empagliflozin in patients with HFrEF and concomitant T2D appears to be safe in terms of renal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12965","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T02:46:57Z","timestamp":1600829217000},"page":"3792-3800","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Renal Function Dynamics Following Co-Administration of Sacubitril\/Valsartan and Empagliflozin in Patients with Heart Failure and Type 2 Diabetes"],"prefix":"10.1093","volume":"7","author":[{"given":"Rafael","family":"de la Espriella","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bay\u00e9s-Gen\u00eds","sequence":"additional","affiliation":[{"name":"CIBER in Cardiovascular Diseases (CIBERCV) , Madrid ,","place":["Spain"]},{"name":"Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, and Department of Medicine, Universitat Autonoma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herminio","family":"Morillas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de D\u00e9nia-MarinaSalud , D\u00e9nia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Bravo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Costa del Sol , Marbella ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Vidal","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital General de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Santas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sanchis","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]},{"name":"CIBER in Cardiovascular Diseases (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"F\u00e1cila","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital General de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Torres","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de D\u00e9nia-MarinaSalud , D\u00e9nia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"G\u00f3rriz","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Valle","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de D\u00e9nia-MarinaSalud , D\u00e9nia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA, Departamento de Medicina, Universitat de Val\u00e8ncia , Valencia ,","place":["Spain"]},{"name":"CIBER in Cardiovascular Diseases (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"2026012114080424900_ehf212965-bib-0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012114080424900_ehf212965-bib-0002","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114080424900_ehf212965-bib-0003","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Failure"},{"key":"2026012114080424900_ehf212965-bib-0004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin\u2013angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diab Endocrinol"},{"key":"2026012114080424900_ehf212965-bib-0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005875","article-title":"Empagliflozin improves kidney outcomes in patients with or without heart failure: insights from the EMPA-REG OUTCOME Trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012114080424900_ehf212965-bib-0006","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114080424900_ehf212965-bib-0007","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114080424900_ehf212965-bib-0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026012114080424900_ehf212965-bib-0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"2026012114080424900_ehf212965-bib-0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10157-018-1673-0","article-title":"Protection of the kidney with sodium\u2013glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials","volume":"23","author":"Kuriyama","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2026012114080424900_ehf212965-bib-0011","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","author":"van Bommel","year":"2019","journal-title":"Kidney Int"},{"key":"2026012114080424900_ehf212965-bib-0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014a position statement from the Heart Failure Association of the European Society of Cardiology: Diuretics in heart failure","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114080424900_ehf212965-bib-0013","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.amjmed.2017.04.007","article-title":"EMPA-REG OUTCOME: the nephrologist's point of view","volume":"130","author":"Wanner","year":"2017","journal-title":"Am J Med"},{"key":"2026012114080424900_ehf212965-bib-0014","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ejhf.1307","article-title":"Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial: acetazolamide in decompensated heart failure with volume overload","volume":"20","author":"Mullens","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114080424900_ehf212965-bib-0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ejhf.746","article-title":"Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure: kidney biomarkers and risk of true worsening renal function and mortality in AHF","volume":"19","author":"Sokolski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114080424900_ehf212965-bib-0016","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","article-title":"Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury","volume":"137","author":"Ahmad","year":"2018","journal-title":"Circulation"},{"key":"2026012114080424900_ehf212965-bib-0017","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1152\/physrev.1990.70.3.665","article-title":"Diverse biological actions of atrial natriuretic peptide","volume":"70","author":"Brenner","year":"1990","journal-title":"Physiol Rev"},{"key":"2026012114080424900_ehf212965-bib-0018","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/S0024-3205(02)01990-2","article-title":"Increased expression of renal neutral endopeptidase in severe heart failure","volume":"71","author":"Knecht","year":"2002","journal-title":"Life Sci"},{"key":"2026012114080424900_ehf212965-bib-0019","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro\u2013B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026012114080424900_ehf212965-bib-0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004644","article-title":"Prognostic significance of creatinine increases during an acute heart failure admission in patients with and without residual congestion: a post hoc analysis of the PROTECT data","volume":"11","author":"Metra","year":"2018","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12965","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3792\/65901311\/eschf_7_6_3792.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3792\/65901311\/eschf_7_6_3792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:08:34Z","timestamp":1769022514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/6\/3792\/8372424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,9,22]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12965","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"2020-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}